Symptom management in a patient with end-stage ovarian cancer: case report

Bowel obstruction is a common complication in patients with far advanced abdominal or pelvic cancer. In patients with recurrent or advanced disease, where options for curative treatment have been exhausted, palliation of symptoms with minimal additional morbidity is the aim of therapy. Owing to the difficulties inherent in conducting perspective randomized trials, clinicians face a significant challenge in managing terminally ill obstructed patients. We evaluated the case of a woman with ovarian cancer. Clinically, the objective of the study was to focus attention on the most up-to-date evidence concerning the treatment of malignant bowel obstruction.

Bowel obstruction; Ovarian cancer; Palliation; Octreotide

[1] Beattie G.J., Leonard R., Smyth J.F.: "Bowel obstruction in ovarian carcinoma: a retrospective study and rewiew of the literature". Pall. Med., 1989, 3, 275.

[2] Gallick H.L., Weaver D.W., Sachs R.J., Bouwman D.L.: "Intesti nal obstruction in cancer patients. An assessment of risk factors and outcome". Am. Sur., 1986, 52, 434.

[3] Van Oojen B., Van Der Burg MEL, Planting ASTh, Siersema P.O., Wiggers T.: "Surgical treatment or gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin". Surg. Gynecol. Obstet., 1993, 176, 469.

[4] Lau P.W., Lorentz T.G.: "Results of Surgery for malignant bowel obstruction in advanced, unresectable, recurrent colorectal cancer". Dis. Col. Rect., 1993, 36, 61.

[5] Baines M., Oliver DJ., Carter R.L.: "Mechanical management of intestinal obstruction in patients with advanced malignant disease: a clinical and pathological study". Lancet, 1985, 11, 990.

[6] Fainsinger R.L., Spachynsky K., Hanson J., Bruera E.: "Symptom control in terminally ill patients with malignant bowel obstruction". J. Pain Symp. Manage., 1994, 9, 12.

[7] Jong P., Sturgeon J., Jameison J.C.: "Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer". Can. J. Surg., 1995, 38, 454.

[8] Freuer D.J., Broadley K.E., Shepherd J.H., Barton D.P.J.: "Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer". Gynecol Oneal., 1999, 75, 313.

[9] Mercadante S.: "A ssessment and management of mechanical bowel obstruction". In: Portenoy R.K., Bruera E., (eds.): "Topics in Palliative Care". New York, Oxford University Press, 1997, 113.

[10] Ripamonti C., Twycross R., Baines M., Bozzetti F.. Capri S., De Conno F. et al.: "Clinical-practice recommendations for the management of bowel obstruction in patients with end stage cancer" Support Care Cancer , 2001, 19, 23.

[11] Pictus D., Marx M.V., Weyman P.J.: "Chronic intestinal obstruction: value of percutaneous gastrostomy tube placement". Am. J Radiol., 1988, 150, 295.

[12] Mercadante S., Ferrera P., Villari P., Marrazzo A.: "Aggressive pharmacological treatment for reversing malignant bowel obstruction". J. Pain Symp. Manage., 2004, 28.

[13] Ripamonti C., Mercadante S.: "Pathophysiology and management of malignant bowel obstruction". In: Doyle D., Hanks G.W.C., MacDonald N., (eds.): "Oxford Textbook of Palliative Medicine", New York, Oxford University press, 2002, 196.

[14] Nellgard P., Bojo L., Cassuto J.: "Importance of vasoactive intestinal peptide and somatostatin for fluid losses in small bowel obstruction". Scand. J. Gastroenterol., 1995, 30, 464.

[15] Jafri S., Posricha P.J.: "Octreotide". In Goodman G.A. (ed.): "Basi Fannacologiche Della Terapia". New York, McGraw Hill, 2003, 988.

[16] Ripamonti C., Mercadante S., Groff L., Zecca E., De Conno F., Casuccio A.: "Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: A prospective randomizedtrial". J. Pain Symp. Manage., 2000, 19.

[17] Matulonis U., Seiden M.V., Roche M., Kranser C., F uller A., Atkinsons T. et al.: "Long acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer". J. Pain Symp. Manage., 2005, 30, 563.

[18] Ripamonti C., Panzeri C., Groff L., Galeazzi G., Boffi R.:'The role of somatostatin and octreotide in bowel obstruction: Pre-clinical and clinical results". Tumori, 2001, 87, 1.

[19] Ventafridda V., Ripamonti C., Caraceni A., Spoldi E., Messina L., De Conno F.: "The management of inoperable gastrointestinal obstruction in terminal cancer patients". Tumori, 1990, 76, 389.

[20] De Conno F., Caraceni A., Zecca E., Spoldi E., Ventafridda V "Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction". J. Pain Symp. Manage., 1991, 6, 484.

[21] Ripamonti C., Fagnoni E., Magni A.: "Management of symptoms due to inoperable bowel obstruction". Tumori, 2005, 91, 233.

[22] Ripamonti C., Gemlo B.T., Bozzetti F., De Conno F.: "Role of enteral nutrition in advanced cancer patients: indications and contraindications of the different techniques employed". Tumori , 1996, 82, 302.

[23] Htinerbein M., Krause M., Moesta K.T., Rau B., Schlag P.M.: "Palliation of malignant rectal obstruction with self-expanding metal stents". Surgery, 2005, 137, 42.

[24] Rao A., Land R, Carter J.: "Management of upper gastrointestinal obstruction in advanced ovarian cancer with intraluminal stents". Gynecol. Oneal., 2004, 95, 739.

[25] Hardy J., Ling J., Mansi J., Isaacs R., Bliss J., A'Hem R et al. "Pitfalls in placebo controlled trials in palliative care: dexametasone for the palliation of malignant bowel obstruction". J. Palliat. Med., 2000, 14, 437.

[26] Chung C.C., Meng WC., Yu S.C., Ceung K.L., Lau WY., Li A.K. "A prospective study on the use of water-soluble contrast follow through radiology in the management of small bowel obstruction". Aust. N. Z. J. Surg., 1996, 66, 598.